Get started
Author

Petra Steindl‐Munda

Observed names: P STEINDLMUNDA, P Steindl-Munda, P. STEINDL‐MUNDA, P. Steindl-Munda, P. Steindl‐Munda, P.E. Steindl-Munda, Petra E. Steindl-Munda, Petra E. SteindlMunda, Petra Steindl-Munda, Petra Steindl–Munda, Steindl-Munda, Petra
Observed institutions: Yamagata University, University of Vienna, Cairo University, Universität Innsbruck, Medical University of Graz, Vienna General Hospital, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Kaiser-Franz-Josef-Spital, Institute of Liver and Biliary Sciences, Scripps Clinic, Cairo University hospitals, Azienda Ospedaliera Universitaria Pisana, Medical University of Vienna
ORCID: 0000-0002-7930-188X
Observed ORCID: 0000-0002-7930-188X
OpenAlex ID: A5008349108
Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis*
2002 · Gerald Mundigler, Georg Delle-Karth, et al. · Critical Care Medicine · 332
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
2008 · Peter Ferenci, Hermann Laferl, et al. · Gastroenterology · 250
Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease
2005 · Peter Ferenci, Petra Steindl-Munda, et al. · Clinical Gastroenterology and Hepatology · 248
PDF
Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy
2008 · Peter Ferenci, Thomas–Matthias Scherzer, et al. · Gastroenterology · 246
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
2003 · Harald Hofer, Thomas Watkins-Riedel, et al. · Hepatology · 201
PDF
Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease
2018 · Peter Ferenci, Wolfgang Stremmel, et al. · Hepatology · 197
Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort
2013 · Sandra Beinhardt, Waltraud Leiss, et al. · Clinical Gastroenterology and Hepatology · 190
Subclinical impairment of brain function in chronic hepatitis C infection
2002 · Ludwig Kramer, Edith Bauer, et al. · Journal of Hepatology · 169
Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C
2010 · Albert Friedrich Stättermayer, Rudolf Stauber, et al. · Clinical Gastroenterology and Hepatology · 168
PDF
Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
2019 · Mattias Mandorfer, Karin Kozbial, et al. · Hepatology · 159
PDF
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a
2002 · Harald Hofer, Hans C. Bankl, et al. · The American Journal of Gastroenterology · 119
Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
2009 · Peter Ferenci, Hermann Laferl, et al. · Gastroenterology · 115
Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection
2011 · Sandra Beinhardt, Judith H. Aberle, et al. · Gastroenterology · 95
PDF
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study
2001 · Wolfgang Jessner, Michael Gschwantler, et al. · The Lancet · 83
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
2020 · Georg Semmler, Teresa Binter, et al. · Hepatology · 75
PDF
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
2010 · Thomas-Matthias Scherzer, Harald Hofer, et al. · Journal of Hepatology · 75
Long‐term follow‐up of chronic hepatitis C patients with sustained virological response to various forms of interferon‐based anti‐viral therapy
2006 · E. FORMANN, P. STEINDL‐MUNDA, et al. · Alimentary Pharmacology & Therapeutics · 75
Prospective study of viral clearance and CD4+ T-cell response in acute hepatitis C primary infection and reinfection
2006 · Judith H. Aberle, Elisabeth Formann, et al. · Journal of Clinical Virology · 74
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
2008 · Peter Ferenci, Harald Brunner, et al. · Hepatology · 73
PDF
Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection
2005 · Ludwig Kramer, Harald Hofer, et al. · AIDS · 67
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection
2005 · Peter Ferenci, Elisabeth Formann, et al. · Journal of Hepatology · 66
PDF
Follow‐up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin‐free treatment
2017 · Karin Kozbial, Stephan Moser, et al. · Liver International · 63
Polymorphisms of interferon-λ4andIL28B- effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C
2013 · A. F. Stättermayer, R. Strassl, et al. · Alimentary Pharmacology & Therapeutics · 55
PDF
Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy
2009 · Martin Krššák, Harald Hofer, et al. · European Journal of Radiology · 54
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C
2012 · Albert Friedrich Stättermayer, Karoline Rutter, et al. · Journal of Hepatology · 52
Works count: 117
Citation count: 4,029
H-index: 32
I10-index: 52
Year
Topic
Type